Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
Study Details
Study Description
Brief Summary
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| The Elderly Undergoing Percutaneous Coronary Intervention Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge. |
Drug: Ticagrelor
Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Types 2, 3, and 5 bleeding, as defined by the Bleeding Academic Research Consortium [12 months]
The primary safety endpoint
- Combined major adverse cardiovascular and cerebrovascular events (MACCEs), including all-cause mortality, myocardial infarction, ischemic stroke, and any revascularization. [12 months]
The primary efficacy endpoint
Secondary Outcome Measures
- All-cause mortality [12 months]
- Myocardial infarction [12 months]
- Revascularization [12 months]
- Ischemic stroke [12 months]
- Incidence of BARC3 and 5 bleeding [12 months]
- Incidence of major and minor bleeding defined by the PLATO study [12 months]
- Incidence of major and minor bleeding defined by the TIMI study [12 months]
- Occurrence of any bleeding [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age≥75 years old;
-
Treated with PCI (limited to stent implantation) ;
-
Survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at discharge;
Exclusion Criteria:
-
Coronary artery bypass graft (CABG) or only drug conservative treatment during hospitalization;
-
Concurrent use of oral anticoagulants;
-
Inability to tolerate long-term antiplatelet therapy, such as active bleeding and a bleeding tendency;
-
Acute infectious diseases;
-
Cognitive impairment;
-
Declined re-examination.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Affiliated Hospital of Dalian Medical University | Dalian | China | 116011 |
Sponsors and Collaborators
- The First Affiliated Hospital of Dalian Medical University
Investigators
- Principal Investigator: Shaoke Meng, MD, The First Affiliated Hospital of Dalian Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
- Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1.
- Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8.
- Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 Aug 18;358(9281):527-33.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
- PJ-KS-KY-2021-146